Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated advanced renal cell carcinoma. 

Belzutifan Has Durable PFS, ORR in Previously Treated Advanced Clear Cell RCC

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer. 

Postsurgical Durvalumab Does Not Boost DFS in Lung Cancer

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer

The Immune Effector Cell Encephalopathy score and keeping a close eye on patients’ symptoms are critical when monitoring for potential ICANS during lymphoma treatment.

Tools to Monitor for ICANS During Lymphoma Treatment With Bispecific Antibodies, CAR T-Cell Therapy

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Caroline Seymour joined MJH Life Sciences in 2018 and has expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

A group of oncology advanced practice providers discussed the use of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma. 

BCMA-Targeted Bispecific Antibodies Are ‘Encouraging’ for Some With Myeloma 

Both community and academic nurses must know what to expect and how to react to adverse events from bispecific antibody treatment in myeloma; however, Donna Catamero, ANP-BC, OCN, CCRC, notes this can be predictable for providers.

AE Profile of Bispecific Antibodies Can Be Predictable in Myeloma Management

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

View

Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma

MonumenTAL-1: Safety and AEs

Larysa Sanchez, MD; and Samantha Shenoy, MSN, NP, discuss the management of adverse events with bispecific antibodies like GPRC5D and talquetamab while providing guidance on optimizing treatment outcomes and supportive care, as well as offering advice for managing toxicities and future perspectives on relapsed/refractory multiple myeloma.

Medical experts  give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies

Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

Experts give an overview of long-term follow-up efficacy data from the MonumenTAL-1 study.

MonumenTAL-1: Long Term Follow up Efficacy

Experts give an overview of safety data from the MonumenTAL-1 study.

Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.

Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.

Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS 

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.

Managing toxicities of BCMA_targeting Bispecfics

MonumenTAL-1: Safety and AEs

EP: 1.Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

EP: 2.MonumenTAL-1: Long Term Follow up Efficacy

EP: 3.MonumenTAL-1: Safety and AEs

EP: 4.Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

EP: 5.Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS

EP: 6.Managing toxicities of BCMA_targeting Bispecfics

Latest Conference Coverage